Immuneel Therapeutics, a cancer treatment company from India, has raised more than Rs 100 crore in a Series B funding round. The company received support from investors such as Singularity AMC, Rainmatter, and other backers. This fresh capital will help the company grow its work in advanced cancer care and reach more patients in India and other countries.
The news has created strong interest in the healthcare and startup sectors. Many experts see this deal as an important step for the future of cancer treatment in India. Immuneel plans to use the money to improve production, lower treatment costs, and increase access to modern therapy for people who fight serious diseases.
The company focuses on cell and gene therapy, which many doctors and scientists now consider one of the most advanced forms of cancer treatment. Immuneel wants to make these therapies more available to patients who often struggle with high medical expenses.
Company Focuses on Advanced Cancer Treatment
Immuneel Therapeutics works in the field of immunotherapy. This treatment helps the human body fight cancer with its own immune system. The company develops CAR-T cell therapy, which many healthcare experts view as a breakthrough in cancer care.
In CAR-T therapy, doctors collect immune cells from a patient’s body. Scientists then change these cells in a lab so they can attack cancer cells more effectively. After this process, doctors place the cells back into the patient’s body. The therapy has shown positive results in several blood cancer cases across the world.
Immuneel wants to make this treatment more affordable and easier to access in India. Many cancer patients travel abroad for such therapies because local options remain limited and costly. The company believes India can become a strong center for advanced cancer care in the future.
Support From Well-Known Investors
The funding round received support from major investors. Singularity AMC and Rainmatter joined the round along with other participants. Rainmatter, which came from Zerodha founders Nithin and Nikhil Kamath, often supports businesses that create social and healthcare impact.
Investor interest in Immuneel shows growing confidence in India’s biotechnology and healthcare sector. Many investors now look at healthcare startups as long-term opportunities because demand for better treatment continues to rise.
Experts believe cancer care and biotech research may become one of the fastest-growing sectors in India during the next decade. The latest investment in Immuneel reflects this larger trend.
Founded With a Strong Vision
Immuneel Therapeutics started in 2018. The company came into existence with support from well-known entrepreneur Kiran Mazumdar-Shaw, who also leads Biocon. She has played a major role in India’s biotechnology sector for many years.
The founders wanted to create a company that could bring world-class cancer treatment to Indian patients at a lower cost. The company has since built research teams, treatment systems, and manufacturing facilities to support this goal.
Immuneel now stands among the important names in India’s cell and gene therapy space. The company continues to expand its medical and scientific capabilities as demand rises.
Funds Will Help Expand Manufacturing
One major goal behind this funding round is expansion of manufacturing capacity. Advanced cancer therapies require special laboratories, equipment, and trained experts. These systems often cost large amounts of money.
Immuneel plans to strengthen its production facilities so it can serve more patients. Better manufacturing capacity may also help reduce waiting time for treatment.
The company believes large-scale production can lower overall treatment costs in the future. This step may help more middle-class families access advanced cancer care without huge financial pressure.
Healthcare experts say India needs stronger local production systems for modern therapies. If companies rely heavily on imports, treatment prices often remain very high. Local manufacturing can change this situation over time.
Company Looks Beyond India
Immuneel also plans to expand its reach outside India. The company wants to enter global markets and build partnerships with international healthcare players.
The worldwide market for cell and gene therapy has grown rapidly during the last few years. Several countries now invest heavily in advanced cancer treatment research. Immuneel hopes to become part of this global healthcare movement.
Indian biotech companies have slowly gained recognition across international markets. Experts believe companies like Immuneel can help place India among important centers for medical innovation.
Global expansion may also create new business opportunities, research partnerships, and treatment access for more patients across regions.
Cancer Cases Continue to Rise
Cancer remains one of the biggest health challenges across the world. India also reports a steady rise in cancer cases every year. Many patients struggle due to late diagnosis, high treatment costs, and limited access to advanced care.
Doctors often say modern therapies can improve survival chances for many patients. However, the cost of such treatments keeps them out of reach for several families.
Immuneel wants to change this situation through local research and production. The company believes India can develop affordable solutions without depending fully on foreign healthcare systems.
Experts say investment in companies like Immuneel may improve the future of cancer treatment in the country. More funding can support research, infrastructure, and medical training.
India’s Biotech Sector Gains Attention
The latest funding round also highlights the growth of India’s biotech industry. During the last few years, investors have shown greater interest in healthcare technology, research, and life sciences.
The COVID-19 pandemic also pushed many countries to focus more on healthcare innovation. India’s strong talent pool and lower research costs have made the country attractive for biotech investment.
Several startups now work in areas such as diagnostics, gene therapy, digital health, and drug research. Immuneel stands out because of its focus on advanced cancer treatment.
Industry experts believe India may become a global biotech hub if companies continue to receive financial and policy support.
Future Plans Remain Ambitious
Immuneel plans to continue research and treatment development in the coming years. The company wants to improve patient access, strengthen manufacturing systems, and build a larger medical network.
The fresh funding may help the company move faster toward these goals. Healthcare experts say strong financial support often plays a major role in biotech growth because research and treatment development require large investments.
Immuneel also hopes to create long-term impact through innovation and affordable care. The company believes cancer patients in India deserve access to modern treatment without extreme financial burden.
As cancer cases rise and healthcare needs grow, companies like Immuneel may shape the future of medical treatment in India. The latest Series B funding marks another important step in that journey.
Also Read – GoDaddy vs Hostinger: Best Startup Domain Choice